AbbVie Seeks Section 337 Import Ban on Humira Biosimilar
AbbVie seeks a ban on imports of adalimumab biosimilars from Alvotech, Teva and Ivers-Lee that allegedly rely on misappropriated trade secrets, it told the International Trade Commission in a Section 337 compaint filed Dec. 17. AbbVie says the companies seek…
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
to bring to market a biologic called AVT02, which is similar to AbbVie’s Humira brand adalimumab, used to treat a variety of conditions such as rheumatoid arthritis, Crohn’s disease and ulcerative colitis. AbbVie seeks a limited exclusion order and cease and desist orders against AlvoTech, Teva and Ivers-Lee. Comments are due to the ITC Jan. 3.